Brief: Monte Rosa Therapeutics Announces Clinical Supply Agreement To Support Phase 2 Trial Evaluating Mrt-2359 In Combination With Apalutamide For The Treatment Of Metastatic Castration-Resistant Prostate Cancer
16/03/2026 11:40
March 16 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O: MONTE ROSA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO SUPPORT PHASE 2 TRIAL EVALUATING MRT-2359 IN COMBINATION WITH APALUTAMIDE FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER MONTE ROSA THERAPEUTICS INC - TO INITIATE PHASE 2 STUDY OF MRT-2359 WITH APALUTAMIDE IN Q3 2026 MONTE ROSA THERAPEUTICS INC - ENTERS SUPPLY AGREEMENT WITH JOHNSON & JOHNSON FOR PHASE 2 MCRPC STUDY STARTING Q3 2026 MONTE ROSA THERAPEUTICS INC - TO CONDUCT AND SPONSOR TRIAL; JOHNSON & JOHNSON TO SUPPLY ERLEADA Source text: ID:nGNX7KKYNT Further company coverage: GLUE.O ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million